Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.

doi:10.1001/jamapsychiatry.2014.3053

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.

JAMA psychiatry - 1 May 2015

Oslin David W, Leong Shirley H, Lynch Kevin G, Berrettini Wade, O'Brien Charles P, Gordon Adam J, Rukstalis Margaret

Abstract excerpt

IMPORTANCE: Alcohol use disorder is one of the leading causes of disability worldwide. While effective pharmacological treatments exist, they are efficacious only in certain individuals, contributing to their limited use. Secondary analysis of clinical trial data suggests that a functional polymorphism (rs1799971, Asn40Asp) of the µ-opioid receptor gene (OPRM1) is associated with the risk of relapse to heavy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Drinking

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alcoholism

Share to Asparagine

Share to Aspartic Acid

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Naltrexone

Share to Narcotic Antagonists

Source

Open in PubMed

Identifiers

PMID: 25760804
DOI: 10.1001/jamapsychiatry.2014.3053

Genes

OPRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.PMID 25760804Read ↗

Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.Semantic proximity Read ↗

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.Semantic proximity Read ↗

Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.Semantic proximity Read ↗

Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.Semantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

Opioid pharmacogenetics of alcohol addiction.Semantic proximity Read ↗

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.Semantic proximity Read ↗

Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.Semantic proximity Read ↗

The μ-opioid receptor and treatment response to naltrexone.Semantic proximity Read ↗

OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.Semantic proximity Read ↗

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.Semantic proximity Read ↗

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.